Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

INV 102 - Invirsa

Next Previous
Drug Profile

INV 102 - Invirsa

Alternative Names: INV-102 Invirsa

Latest Information Update: 18 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Invirsa
  • Class Adenine nucleotides; Anti-infectives; Anti-inflammatories; Antivirals; Eye disorder therapies; Small molecules
  • Mechanism of Action DNA repair enzyme stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Infectious keratoconjunctivitis
  • Phase I/II Dry eyes
  • Research Respiratory tract infections

Most Recent Events

  • 06 Mar 2024 Phase-II clinical trials in Infectious keratoconjunctivitis in USA (Ophthalmic) (NCT05636228)
  • 05 Sep 2023 Invirsa plans a phase II clinical trial in Infectious keratoconjunctivitis in USA (Ophthalmic) (NCT05636228)
  • 05 Sep 2023 Invirsa suspends a phase II clinical trial in Infectious keratoconjunctivitis in Thailand (Ophthalmic) due to the study being closed in Thailand and opened in the USA (NCT05636228)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top